false 0000786947 0000786947 2024-05-31 2024-05-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act Of 1934

 

Date of Report (Date of earliest event reported): May 31, 2024

___________________________________________________________

 

ACURA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

___________________________________________________________

  

New York 1-10113 11-0853640
(State or other jurisdiction of incorporation (Commission File Number) (I.R.S. Employer Identification Number)

 

616 N. North Court, Suite 120

Palatine, Illinois 60067

(Address of principal executive offices) (Zip code)

 

(847)705-7709

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))

 

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.01 par value per share ACUR

OTC Market – OTC Expert Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging Growth Company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On May 31, 2024, Peter A. Clemens, Sr. Vice President and Chief Financial Officer of Acura Pharmaceuticals, Inc. and its subsidiary, Acura Pharmaceutical Technologies, Inc (the “Company”), notified the Board of Directors (the “Board”) of his retirement, effective September 30, 2024. In connection with Mr. Clemens’s retirement, the Board has approved or ratified the following actions.

 

Although Mr. Clemens will remain an employee of the Company as Vice President until the end of September to ensure a smooth transition, he is stepping down as Chief Financial Officer, effective July 31, 2024.

 

Also on May 31, 2024, Robert A. Seiser was appointed as Sr. Vice President and Chief Financial Officer, effective August 1, 2024. Mr. Seiser, age 60, is currently Vice President Treasurer and Corporate Controller of the Company, a position he has held since 1998.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  ACURA PHARMACEUTICALS, INC.
   
  By: /s/ Peter A. Clemens
    Peter A. Clemens
    Senior Vice President & Chief Financial Officer

 

Date:      June 4, 2024

 

 

 

v3.24.1.1.u2
Cover
May 31, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 31, 2024
Entity File Number 1-10113
Entity Registrant Name ACURA PHARMACEUTICALS, INC.
Entity Central Index Key 0000786947
Entity Tax Identification Number 11-0853640
Entity Incorporation, State or Country Code NY
Entity Address, Address Line One 616 N. North Court
Entity Address, Address Line Two Suite 120
Entity Address, City or Town Palatine
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60067
City Area Code 847
Local Phone Number 705-7709
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value per share
Trading Symbol ACUR
Entity Emerging Growth Company false
Acura Pharmaceuticals (CE) (USOTC:ACUR)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024 Click aqui para mais gráficos Acura Pharmaceuticals (CE).
Acura Pharmaceuticals (CE) (USOTC:ACUR)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024 Click aqui para mais gráficos Acura Pharmaceuticals (CE).